Display options
Cite
Sherif NA, El-Banna AS, ElBourini MM, et al. Efficacy of L-carnitine and propranolol in the management of acute theophylline toxicity. Toxicol Res (Camb). 2020;9(1):45-54doi: 10.1093/toxres/tfaa002.
Sherif, N. A., El-Banna, A. S., ElBourini, M. M., & Khalil, N. O. (2020). Efficacy of L-carnitine and propranolol in the management of acute theophylline toxicity. Toxicology research, 9(1), 45-54. https://doi.org/10.1093/toxres/tfaa002
Sherif, Naima A, et al. "Efficacy of L-carnitine and propranolol in the management of acute theophylline toxicity." Toxicology research vol. 9,1 (2020): 45-54. doi: https://doi.org/10.1093/toxres/tfaa002
Sherif NA, El-Banna AS, ElBourini MM, Khalil NO. Efficacy of L-carnitine and propranolol in the management of acute theophylline toxicity. Toxicol Res (Camb). 2020 Mar 11;9(1):45-54. doi: 10.1093/toxres/tfaa002. eCollection 2020 Feb. PMID: 32440337; PMCID: PMC7233323.
Copy Download .nbib Format: NLM
Share it on

Toxicol Res (Camb). 2020 Mar 11;9(1):45-54. doi: 10.1093/toxres/tfaa002. eCollection 2020 Feb.

Efficacy of L-carnitine and propranolol in the management of acute theophylline toxicity.

Toxicology research

Naima A Sherif, Asmaa S El-Banna, Marwan M ElBourini, Nancy O Khalil

Affiliations

  1. Department of Forensic Medicine& Clinical Toxicology-Faculty of Medicine, Alexandria University, Egypt.
  2. Critical Care Medicine, Faculty of Medicine, Alexandria University, Egypt.

PMID: 32440337 PMCID: PMC7233323 DOI: 10.1093/toxres/tfaa002

Abstract

Theophylline toxicity results in substantial morbidity and mortality particularly due to its narrow therapeutic index. The development of new treatments for acute theophylline toxicity is a point of research interest. The aim of the present work was to assess the efficacy of L-carnitine (LC) and propranolol in the management of patients with acute theophylline toxicity. The study was conducted on 60 patients with acute theophylline toxicity admitted to the Poison Control Center or Intensive Care Unit at Alexandria Main University Hospital. The studied patients were equally classified into four groups (GPs, 15 patients each): the first group was the control group who received standard treatment protocol for theophylline toxicity. The other three GPs also received standard treatment protocol for theophylline toxicity in addition. The second group (LC group) received LC with a loading dose of 100 mg/kg IV over 30-60 min (maximum 6 g) and the maintenance dose was 50 mg/kg IV every 8 h. The third group (propranolol group) received propranolol, administered slowly intravenous 0.5-1 mg over 1 min; it may be repeated if necessary up to a total maximum dose of 0.1 mg/kg. The fourth group (propranolol and LC) received both IV propranolol and LC in the same doses as previous. Treatment with LC alone or in combination with propranolol resulted in a significant improvement of both clinical and laboratory findings. Although combined therapy yields the best results and outcome, LC can serve as an antidote for acute theophylline toxicity if there is any contraindication to propranolol administration.

© The Author(s) 2020. Published by Oxford University Press.

Keywords: L-carnitine; acute theophylline toxicity; antioxidants; propranolol; β-blocker

References

  1. Med Sci Monit. 2011 Jan;17(1):BR1-9 - PubMed
  2. J Clin Invest. 1989 Jun;83(6):1800-9 - PubMed
  3. Pharmaceuticals (Basel). 2010 Mar 18;3(3):725-747 - PubMed
  4. Prog Cardiovasc Dis. 1997 Nov-Dec;40(3):265-86 - PubMed
  5. Handb Exp Pharmacol. 2011;(200):251-66 - PubMed
  6. Mediators Inflamm. 2012;2012:492901 - PubMed
  7. Adv Myocardiol. 1985;5:183-9 - PubMed
  8. Turk J Pediatr. 2016;58(3):297-300 - PubMed
  9. Am J Emerg Med. 1993 Nov;11(6):609-10 - PubMed
  10. Intensive Care Med. 1996 Jun;22(6):585-7 - PubMed
  11. Ann Pharmacother. 2010 Jul-Aug;44(7-8):1287-93 - PubMed
  12. Am J Physiol. 1987 Feb;252(2 Pt 2):H252-7 - PubMed
  13. Ann Intern Med. 1991 May 1;114(9):748-53 - PubMed
  14. Indian J Exp Biol. 2005 Oct;43(10):849-53 - PubMed
  15. Jpn Heart J. 1981 Mar;22(2):219-25 - PubMed
  16. J Clin Pharmacol. 1977 Oct;17(10 Pt 1):561-8 - PubMed
  17. Acta Anaesthesiol Scand. 2011 Sep;55(8):1022-8 - PubMed
  18. Eur J Heart Fail. 2000 Jun;2(2):189-93 - PubMed
  19. Ann Emerg Med. 1991 Oct;20(10):1135-7 - PubMed
  20. Ren Fail. 2010;32(9):1109-14 - PubMed
  21. Turk J Emerg Med. 2018 Jan 05;18(1):37-39 - PubMed
  22. Pharmacol Biochem Behav. 2005 Sep;82(1):241-5 - PubMed
  23. Ann Emerg Med. 1990 Jun;19(6):671-3 - PubMed
  24. Br J Pharmacol. 1984 Jun;82(2):533-42 - PubMed
  25. J Physiol Pharmacol. 2004 Sep;55(3):595-606 - PubMed
  26. Emerg Nurse. 2001 Feb;8(9):24-9 - PubMed
  27. Mutat Res. 2008 Feb 29;650(2):165-74 - PubMed
  28. J Cardiol. 1991;21(2):493-504 - PubMed
  29. Lab Invest. 1982 Nov;47(5):412-26 - PubMed
  30. Pharmacotherapy. 1995 Jul-Aug;15(4):409-27 - PubMed
  31. Arch Intern Med. 1999 May 10;159(9):989-94 - PubMed
  32. Gene. 2014 Jan 10;533(2):469-76 - PubMed
  33. Am J Kidney Dis. 2003 Apr;41(4 Suppl 4):S35-43 - PubMed
  34. J Nutr Biochem. 2006 Feb;17(2):73-88 - PubMed

Publication Types